![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » AbbVie Enters Partnership to Develop COVID-19 Antibody Therapies
AbbVie Enters Partnership to Develop COVID-19 Antibody Therapies
![Partner Up, blocks](https://www.fdanews.com/ext/resources/test/Drug-Images4/Partner-Up-blocks.gif?t=1593635821&width=430)
AbbVie has entered a partnership with Harbour BioMed (HBM), Utrecht University (UU) and Erasmus Medical Center (EMC) to develop a monoclonal antibody therapy for COVID-19.
The partnership will advance the fully human, neutralizing antibody 47D11 discovered by UU, EMC and HBM. The drugmaker will support its partners through preclinical activities while preparing for later-stage preclinical and clinical development work.
The company will have the option to exclusively license the antibody for therapeutic clinical development and commercialization worldwide.
Upcoming Events
-
21Oct